Document Detail


Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study.
MedLine Citation:
PMID:  21868086     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The diagnosis of hypertension has traditionally been based on blood-pressure measurements in the clinic, but home and ambulatory measurements better correlate with cardiovascular outcome, and ambulatory monitoring is more accurate than both clinic and home monitoring in diagnosing hypertension. We aimed to compare the cost-effectiveness of different diagnostic strategies for hypertension.
METHODS: We did a Markov model-based probabilistic cost-effectiveness analysis. We used a hypothetical primary-care population aged 40 years or older with a screening blood-pressure measurement greater than 140/90 mm Hg and risk-factor prevalence equivalent to the general population. We compared three diagnostic strategies-further blood pressure measurement in the clinic, at home, and with an ambulatory monitor-in terms of lifetime costs, quality-adjusted life years, and cost-effectiveness.
FINDINGS: Ambulatory monitoring was the most cost-effective strategy for the diagnosis of hypertension for men and women of all ages. It was cost-saving for all groups (from -£56 [95% CI -105 to -10] in men aged 75 years to -£323 [-389 to -222] in women aged 40 years) and resulted in more quality-adjusted life years for men and women older than 50 years (from 0·006 [0·000 to 0·015] for women aged 60 years to 0·022 [0·012 to 0·035] for men aged 70 years). This finding was robust when assessed with a wide range of deterministic sensitivity analyses around the base case, but was sensitive if home monitoring was judged to have equal test performance to ambulatory monitoring or if treatment was judged effective irrespective of whether an individual was hypertensive.
INTERPRETATION: Ambulatory monitoring as a diagnostic strategy for hypertension after an initial raised reading in the clinic would reduce misdiagnosis and save costs. Additional costs from ambulatory monitoring are counterbalanced by cost savings from better targeted treatment. Ambulatory monitoring is recommended for most patients before the start of antihypertensive drugs.
FUNDING: National Institute for Health Research and the National Institute for Health and Clinical Excellence.
Authors:
Kate Lovibond; Sue Jowett; Pelham Barton; Mark Caulfield; Carl Heneghan; F D Richard Hobbs; James Hodgkinson; Jonathan Mant; Una Martin; Bryan Williams; David Wonderling; Richard J McManus
Related Documents :
8650606 - Effects of granulocyte colony-stimulating factor in severe pancreatitis.
12617236 - Low pressure hydrocephalus and ventriculomegaly: hysteresis, non-linear dynamics, and t...
10392536 - Cholecystokinin peptides in cerebrospinal fluid: a study in healthy male subjects lumba...
469556 - Papilloedema, csf pressure, and csf flow in cerebral tumours.
15956086 - Acute pressor and hormonal effects of beta-endorphin at high doses in healthy and hyper...
8178886 - Recovery of the ovine fetus from sustained hypoxia: effects on endocrine, cardiovascula...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-08-23
Journal Detail:
Title:  Lancet     Volume:  378     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-10-03     Completed Date:  2011-10-19     Revised Date:  2012-05-09    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  1219-30     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2011 Elsevier Ltd. All rights reserved.
Affiliation:
National Clinical Guideline Centre, Royal College of Physicians, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Blood Pressure Monitoring, Ambulatory* / economics
Cardiovascular Diseases / etiology,  mortality
Cost-Benefit Analysis
Costs and Cost Analysis
England
Female
Humans
Hypertension / complications,  diagnosis*,  economics,  physiopathology
Male
Markov Chains
Middle Aged
Models, Statistical
Quality-Adjusted Life Years
Risk Factors
Sensitivity and Specificity
Comments/Corrections
Comment In:
Lancet. 2011 Oct 1;378(9798):1199-200   [PMID:  21868084 ]
Lancet. 2012 Feb 25;379(9817):709-10; author reply 710   [PMID:  22364755 ]
Rev Clin Esp. 2012 Apr;212(4):206   [PMID:  22570883 ]
Erratum In:
Lancet. 2011 Oct 1;378(9798):1218

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The cryoglobulinaemias.
Next Document:  Short-term variability of multiple biomarker response in fish from estuaries: Influence of environme...